MX390899B - Formulación de combinación de dosis fija, eflornitina y sulindaco. - Google Patents

Formulación de combinación de dosis fija, eflornitina y sulindaco.

Info

Publication number
MX390899B
MX390899B MX2018005350A MX2018005350A MX390899B MX 390899 B MX390899 B MX 390899B MX 2018005350 A MX2018005350 A MX 2018005350A MX 2018005350 A MX2018005350 A MX 2018005350A MX 390899 B MX390899 B MX 390899B
Authority
MX
Mexico
Prior art keywords
eflornithine
sulindac
dose combination
fixed dose
combination formulation
Prior art date
Application number
MX2018005350A
Other languages
English (en)
Spanish (es)
Other versions
MX2018005350A (es
Inventor
Jean Ducassou
Patrick Shannon
Gonzalez Roberto Carlos Bravo
Original Assignee
Cancer Prevention Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Prevention Pharmaceuticals Inc filed Critical Cancer Prevention Pharmaceuticals Inc
Priority claimed from PCT/US2016/059689 external-priority patent/WO2017075576A1/en
Publication of MX2018005350A publication Critical patent/MX2018005350A/es
Publication of MX390899B publication Critical patent/MX390899B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2018005350A 2015-10-30 2016-10-31 Formulación de combinación de dosis fija, eflornitina y sulindaco. MX390899B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562248810P 2015-10-30 2015-10-30
US201662358698P 2016-07-06 2016-07-06
EP16306430 2016-10-28
EP16306429 2016-10-28
PCT/US2016/059689 WO2017075576A1 (en) 2015-10-30 2016-10-31 Eflornithine and sulindac, fixed dose combination formulation

Publications (2)

Publication Number Publication Date
MX2018005350A MX2018005350A (es) 2018-08-14
MX390899B true MX390899B (es) 2025-03-21

Family

ID=57256487

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005350A MX390899B (es) 2015-10-30 2016-10-31 Formulación de combinación de dosis fija, eflornitina y sulindaco.

Country Status (14)

Country Link
US (4) US10973790B2 (cg-RX-API-DMAC7.html)
EP (1) EP3368029A1 (cg-RX-API-DMAC7.html)
JP (3) JP2018536707A (cg-RX-API-DMAC7.html)
KR (2) KR20240162560A (cg-RX-API-DMAC7.html)
CN (1) CN108366982A (cg-RX-API-DMAC7.html)
AU (1) AU2016343851B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018008651A2 (cg-RX-API-DMAC7.html)
CA (1) CA3003149C (cg-RX-API-DMAC7.html)
CL (1) CL2018001157A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018005491A2 (cg-RX-API-DMAC7.html)
HK (1) HK1258284A1 (cg-RX-API-DMAC7.html)
IL (1) IL259009A (cg-RX-API-DMAC7.html)
MA (1) MA43114A (cg-RX-API-DMAC7.html)
MX (1) MX390899B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX390899B (es) * 2015-10-30 2025-03-21 Cancer Prevention Pharmaceuticals Inc Formulación de combinación de dosis fija, eflornitina y sulindaco.
AU2017339781B2 (en) * 2016-10-06 2022-03-17 Orbus Therapeutics, Inc. Formulations for administration of eflornithine
US10945981B2 (en) 2019-05-17 2021-03-16 Cancer Prevention Pharmaceuticals, Inc. Methods for treating familial adenomatous polyposis
CN119909027B (zh) * 2025-01-21 2025-11-18 福安药业集团宁波天衡制药有限公司 一种稳定的舒林酸片及其制备方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4330559A (en) 1977-07-11 1982-05-18 Merrell-Toraude Et Cie Method of treating benign prostatic hypertrophy
US4309442A (en) * 1977-07-11 1982-01-05 Merrell Toraude Et Compagnie Method for controlling fertility in mammals
US4413141A (en) 1977-07-11 1983-11-01 Merrell Toraude Et Compagnie 2-(Difluoromethyl)-2,5-diaminopentanoic acid
US4499072A (en) 1982-11-29 1985-02-12 Merrell Dow Pharmaceuticals Inc. Process for treating diseases with ODC inhibitors
US4859452A (en) 1986-01-17 1989-08-22 Board Of Regents, The University Of Texas System Methods for the reduction of difluoromethylornithine associated toxicity
US4925835A (en) 1986-05-01 1990-05-15 Sloan-Kettering Institute For Cancer Research Aziridinyl putrescine containing compositions and their uses in treating prostate cancer
US5002879A (en) 1986-05-06 1991-03-26 Merrell Dow Pharmaceuticals Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor
FR2706255B1 (fr) 1993-06-17 1995-10-27 Univ Rennes Composition à usage alimentaire et/ou pharmaceutique pauvre en polyamines et applications thérapeutiques.
US5843929A (en) 1996-03-22 1998-12-01 Mayo Foundation For Medical Education And Research Chemoprevention of metachronous adenomatous colorectal polyps
JP2000507613A (ja) * 1996-11-01 2000-06-20 アイレックス・オンコロジー・インコーポレイテッド Ｄｆｍｏ含有持続放出配合物
US6486214B1 (en) 1997-09-10 2002-11-26 Rutgers, The State University Of New Jersey Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby
WO1999049859A1 (en) * 1998-03-28 1999-10-07 The Arizona Board Of Regents On Behalf Of The University Of Arizona Dfmo and sulindac combination in cancer chemoprevention
US7700568B2 (en) 1998-06-30 2010-04-20 Sloan-Kettering Institute For Cancer Research Uses of DNA-PK
AU783992B2 (en) 1998-12-23 2006-01-12 G.D. Searle Llc Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20050037090A1 (en) 1998-12-23 2005-02-17 Mckearn John P. Combination therapy including a cyclooxygenase-2 inhibitor and an antineoplastic agent
US6753422B2 (en) 1999-03-01 2004-06-22 O'brien Thomas G. Odc allelic analysis method for assessing carcinogenic susceptibility
CA2373931A1 (en) 1999-05-17 2000-11-23 Richard Love Dfmo and celecoxib in combination for cancer chemoprevention and therapy
WO2001068076A2 (en) 2000-03-07 2001-09-20 Ilex Oncology, Inc. D-enantiomer of dfmo and methods of use thereof for treating cancer
US6602910B2 (en) 2000-03-07 2003-08-05 Ilex Oncology, Inc. D-enantiomer of DFMO and methods of use therefor
EP1351675A2 (en) 2000-08-24 2003-10-15 The Regents of the University of California Alpha-difluoromethylornithine (dfmo) use in the human prostate
GB0125492D0 (en) 2001-10-24 2001-12-12 Astrazeneca Ab Formulation
US7273888B2 (en) 2001-11-16 2007-09-25 Als Therapy Development Foundation, Inc. Use of difluoromethylornithine (DFMO) for the treatment of amyotrophic lateral sclerosis
JP2006515861A (ja) 2002-11-29 2006-06-08 フォレスト ラボラトリーズ インコーポレーテッド イブプロフェンとオキシコドンを含有する単位剤形での急性痛の治療方法
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20070043097A1 (en) * 2005-07-18 2007-02-22 Horizon Therapeutics, Inc. Medicaments containing famotidine and ibuprofen and administration of same
WO2007075673A1 (en) 2005-12-20 2007-07-05 University Of Hawaii Treatment regimen for n-myc, c-myc, and l-myc amplified and overexpressed tumors
AU2007275360B2 (en) 2006-07-18 2013-05-16 Horizon Medicines Llc Methods and medicaments for administration of ibuprofen
CN101801351B (zh) * 2007-07-19 2012-12-12 武田药品工业株式会社 包含阿格列汀和盐酸二甲双胍的固体制剂
US8829021B2 (en) 2007-08-01 2014-09-09 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Treatment of pediatric tumors
WO2009022670A1 (ja) * 2007-08-10 2009-02-19 Takeda Pharmaceutical Company Limited 速崩壊性錠剤
US8283331B2 (en) 2007-10-09 2012-10-09 Children's Medical Center Corporation Methods to regulate miRNA processing by targeting Lin-28
WO2009052518A2 (en) * 2007-10-19 2009-04-23 Aspen Benefits Group, Llc Methods and compositions directed to reduction of facial hair hirsutism in females
EP3028743A3 (en) 2008-03-05 2017-01-25 Vicus Therapeutics, LLC Compositions for mucositis and oncology therapies
US20100120727A1 (en) 2008-11-12 2010-05-13 Kyphia Pharmaceuticals, Inc. Eflornithine Prodrugs, Conjugates and Salts, and Methods of Use Thereof
ES2639444T3 (es) 2008-12-08 2017-10-26 The Procter & Gamble Company Composición para la higiene personal en forma de un artículo que tiene un recubrimiento hidrófobo que reside en la superficie
CA2761946A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of California, A California Corporation Carcinoma diagnosis and treatment, based on odc1 genotype
EP2432553A2 (en) 2009-05-20 2012-03-28 Ranbaxy Laboratories Limited Liquid dosage forms of isotretinoin
CN101898978A (zh) 2009-05-31 2010-12-01 徐锋 依氟鸟氨酸前药和偶合物及其使用方法
US20110256161A1 (en) 2010-04-19 2011-10-20 Aminex Therapeutics Inc. Methods for enhancing immune response
WO2011135459A2 (en) 2010-04-29 2011-11-03 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy
JP6083646B2 (ja) 2010-05-14 2017-02-22 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナＡｒｉｚｏｎａ Ｂｏａｒｄ ｏｆ Ｒｅｇｅｎｔｓ ｏｎ ｂｅｈａｌｆ ｏｆ ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ａｒｉｚｏｎａ 食事性ポリアミン含量に基づく癌予防及び治療法
US8853423B2 (en) * 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
CN103347894B (zh) 2010-06-19 2017-05-10 纪念斯隆-凯特林癌症中心 抗gd2抗体
HUE040263T2 (hu) 2012-10-29 2019-02-28 Arizona Board Of Regents On Behalf Of Univ Of Arizona Prediktív markerek poliamin-inhibitor rákterápiákhoz
GB2513299A (en) 2013-03-12 2014-10-29 Cellact Pharma Gmbh Biomedizinzentrum Compounds for targeting cancer stem cells
JP6574415B2 (ja) * 2013-10-07 2019-09-11 ブリストル−マイヤーズ・スクイブ・ホールディングス・アイルランド・アンリミテッド・カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｈｏｌｄｉｎｇｓ Ｉｒｅｌａｎｄ Ｕｎｌｉｍｉｔｅｄ Ｃｏｍｐａｎｙ アタザナビルおよびコビシスタットのｈｉｖ治療製剤
KR20150079373A (ko) * 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
CA2952771A1 (en) 2014-06-18 2015-12-23 Arizona Board Of Regents On Behalf Of The University Of Arizona Carcinoma diagnosis and treatment based on odc1 genotype
WO2016130918A1 (en) 2015-02-12 2016-08-18 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating neuroblastoma
WO2017075576A1 (en) 2015-10-30 2017-05-04 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation
MX390899B (es) * 2015-10-30 2025-03-21 Cancer Prevention Pharmaceuticals Inc Formulación de combinación de dosis fija, eflornitina y sulindaco.

Also Published As

Publication number Publication date
US20240173284A1 (en) 2024-05-30
JP2022028814A (ja) 2022-02-16
JP2018536707A (ja) 2018-12-13
HK1258284A1 (zh) 2019-11-08
MA43114A (fr) 2018-09-05
US20230172887A1 (en) 2023-06-08
MX2018005350A (es) 2018-08-14
BR112018008651A2 (pt) 2018-10-30
KR20180069068A (ko) 2018-06-22
CL2018001157A1 (es) 2018-09-07
US20210267926A1 (en) 2021-09-02
AU2016343851A1 (en) 2018-05-10
US10973790B2 (en) 2021-04-13
CO2018005491A2 (es) 2018-06-12
US12350246B2 (en) 2025-07-08
AU2016343851B2 (en) 2022-04-07
CA3003149C (en) 2023-10-31
IL259009A (en) 2018-07-31
CA3003149A1 (en) 2017-05-04
US20200009098A1 (en) 2020-01-09
JP2024102339A (ja) 2024-07-30
EP3368029A1 (en) 2018-09-05
CN108366982A (zh) 2018-08-03
KR20240162560A (ko) 2024-11-15
US11925613B2 (en) 2024-03-12
JP7592001B2 (ja) 2024-11-29
US11529326B2 (en) 2022-12-20

Similar Documents

Publication Publication Date Title
CY1125326T1 (el) Προαιρετικως συντηγμενα ετεροκυκλυλο- υποκατεστημενα παραγωγα πυριμιδινης χρησιμα για τη θεραπευτικη αγωγη φλεγμονωδων, μεταβολικων, ογκολογικων και αυτοανοσων ασθενειων.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
IL256652A (en) Therapeutic compositions, combinations, and methods of use
LT3513809T (lt) Medicininė kompozicija, apimanti tivozanibą
EP4233846C0 (en) PHARMACEUTICAL FORMULATIONS
DK3684333T3 (da) Valbenazin-formulering med høj dosis og sammensætninger, fremgangsmåder og kits relateret hertil
BR112016018062A2 (pt) compostos terapêuticos, composição farmacêutica e usos
IL291601A (en) Neoglycoconjugates as vaccines and therapeutic tools
IL259067B (en) New chryptophan compounds and conjugates, their preparation and therapeutic use
MX2022005372A (es) Combinaciones y formulaciones de dosis fijas que comprenden etc-1002 y una o mas estatinas.
MX2019014772A (es) Formulaciones en gel de bisfosfocinas y usos de estas.
IL253619B (en) Encapsulation of high potency active agents
CL2017002299A1 (es) Combinaciones de dosis fija y formulaciones comprendiendo etc-1002 y ezetimiba y métodos para tratar o reducir el riesgo de enfermedades cardiovasculares
CY1122473T1 (el) Βελτιστοποιημενο μεσαλαζiνουχο δισκιο υψηλης δοσης
IL266279B1 (en) Stable aqueous capsaicin injectable formuatlions and medical uses thereof
CL2018003338A1 (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
EP3630113A4 (en) PHARMACEUTICAL COMPOSITION INCLUDING A PDE9 INHIBITOR
BR112017013012A2 (pt) compostos de indenil, composições farmacêuticas e usos médicos destes
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
MX390899B (es) Formulación de combinación de dosis fija, eflornitina y sulindaco.
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
EP3746080A4 (en) PHARMACEUTICAL FORMULATIONS
DK3324736T3 (da) Hidtil ukendt spot-on-aktivstofformulering
PH12018501991A1 (en) Pharmaceutical composition for use in treating fibrosis
EP3651800C0 (en) HYDROCOMPRESSED PHARMACEUTICAL FORMULATIONS